Thienopyrimidine derivatives as ACC inhibitors and uses thereof

US11352371B2 · kind B2 · utility

Assignee

• Gilead Sciences, Inc. · US

Inventors

• Jamie Geier Bates · Burlingame, US
• Ana Z. Gonzalez Buenrostro · San Mateo, US
• Hongyan Guo · San Mateo, US
• Xiaochun Han · Sunnyvale, US
• Brian Kirby · Redwood City, US
• Yurong Lai · Dublin, US
• Michael L. Mitchell · Union City, US
• Gregg M. Schwarzwalder · Redwood City, US
• James G. Taylor · Burlingame, US
• Ting Wang · Beijing, CN

Key dates

• Filing date: Aug 6, 2020
• Grant date: Jun 7, 2022
• Expiry date: Sep 30, 2040

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P1/16
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present disclosure relates generally to thienopyrimidine compounds that bind to Acetyl-CoA Carboxylase (ACC) and act as inhibitors of ACC. The disclosure further relates to the use of the thienopyrimidine compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of ACC, including liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).